|
1.
|
M HidalgoPancreatic cancerN Engl J
Med36216051617201010.1056/NEJMra0901557
|
|
2.
|
VT DeVita JrA step in the right
directionNat Clin Pract Oncol3641200610.1038/ncponc066917139311
|
|
3.
|
KH TkaczukReview of the contemporary
cytotoxic and biologic combinations available for the treatment of
metastatic breast cancerClin
Ther3122732289200910.1016/j.clinthera.2009.11.01120110041
|
|
4.
|
J GoffinC LacchettiPM EllisYC UngWK
EvansFirst-line systemic chemotherapy in the treatment of advanced
non-small cell lung cancer: a systematic reviewJ Thorac
Oncol5260274201010.1097/JTO.0b013e3181c6f035
|
|
5.
|
S NagelR CalifanoN ThatcherF
BlackhallGemcitabine and carboplatin in combination for the
treatment of advanced, metastatic, non-small cell lung cancerExpert
Opin
Pharmacother832653275200710.1517/14656566.8.18.326518035969
|
|
6.
|
DA FennellG GaudinoKJ O’ByrneL MuttiJ van
MeerbeeckAdvances in the systemic therapy of malignant pleural
mesotheliomaNat Clin Pract
Oncol5136147200810.1038/ncponc103918227828
|
|
7.
|
M RayHL KindlerMalignant pleural
mesothelioma: an update on biomarkers and
treatmentChest136888896200910.1378/chest.08-266519736192
|
|
8.
|
P JantscheffN EsserR GraeserLiposomal
gemcitabine (GemLip)-efficient drug against hormone-refractory
Du145 and PC-3 prostate cancer
xenograftsProstate6911511163200910.1002/pros.2096419399788
|
|
9.
|
P JantscheffV ZiroliN EsserAnti-metastatic
effects of liposomal gemcitabine in a human orthotopic LNCaP
prostate cancer xenograft modelClin Exp
Metastasis26981992200910.1007/s10585-009-9288-119784785
|
|
10.
|
W PlunkettP HuangYZ XuV HeinemannR
GrunewaldV GandhiGemcitabine: metabolism, mechanisms of action, and
self-potentiationSemin Oncol22Suppl 1131019957481842
|
|
11.
|
MW LawlessS NorrisKJ O’ByrneSG
GrayTargeting histone deacetylases for the treatment of diseaseJ
Cell Mol
Med13826852200910.1111/j.1582-4934.2008.00571.x19175682
|
|
12.
|
KJ O’ByrneMP BarrSG GrayThe role of
epigenetics in resistance to cisplatin chemotherapy in lung
cancerCancers314261453201124212667
|
|
13.
|
D CaiDS ShamesMG RasoSteroid receptor
coactivator-3 expression in lung cancer and its role in the
regulation of cancer cell survival and proliferationCancer
Res7064776485201010.1158/0008-5472.CAN-10-000520663904
|
|
14.
|
N HajjiK WallenborgP VlachosJ FullgrabeO
HermansonB JosephOpposing effects of hMOF and SIRT1 on H4K16
acetylation and the sensitivity to the topoisomerase II inhibitor
etoposideOncogene2921922204201010.1038/onc.2009.50520118981
|
|
15.
|
W ZhaoQ ZhangX KangS JinC LouAIB1 is
required for the acquisition of epithelial growth factor
receptor-mediated tamoxifen resistance in breast cancer
cellsBiochem Biophys Res
Commun380699704200910.1016/j.bbrc.2009.01.15519285025
|
|
16.
|
SB BaylinPA JonesA decade of exploring the
cancer epigenome - biological and translational implicationsNat Rev
Cancer11726734201110.1038/nrc313021941284
|
|
17.
|
SD GoreC JonesP KirkpatrickDecitabineNat
Rev Drug Discov5891892200610.1038/nrd218017117522
|
|
18.
|
E KaminskasA FarrellS AbrahamApproval
summary: azacitidine for treatment of myelodysplastic syndrome
subtypesClin Cancer
Res1136043608200510.1158/1078-0432.CCR-04-213515897554
|
|
19.
|
T YokochiKD RobertsonDoxorubicin inhibits
DNMT1, resulting in conditional apoptosisMol
Pharmacol6614151420200410.1124/mol.104.00263415340041
|
|
20.
|
SG GrayN Al-SarrafAM BairdMC CathcartE
McGovernKJ O’ByrneRegulation of EP receptors in non-small cell lung
cancer by epigenetic modificationsEur J
Cancer4530873097200910.1016/j.ejca.2009.09.00619818596
|
|
21.
|
PW LairdA ZijderveldK LindersMA RudnickiR
JaenischA BernsSimplified mammalian DNA isolation procedureNucleic
Acids Res194293199110.1093/nar/19.15.42931870982
|
|
22.
|
A DaskalosS LogothetiS MarkopoulouGlobal
DNA hypomethylation-induced DeltaNp73 transcriptional activation in
non-small cell lung cancerCancer
Lett3007986201110.1016/j.canlet.2010.09.00920926182
|
|
23.
|
A DaskalosG NikolaidisG
XinarianosHypomethylation of retrotransposable elements correlates
with genomic instability in non-small cell lung cancerInt J
Cancer1248187200910.1002/ijc.2384918823011
|
|
24.
|
A DaskalosU OleksiewiczA
FiliaUHRF1-mediated tumor suppressor gene inactivation in nonsmall
cell lung cancerCancer11710271037201110.1002/cncr.2553121351083
|
|
25.
|
B HeAY LeeS DadfarmaySecreted
frizzled-related protein 4 is silenced by hypermethylation and
induces apoptosis in beta-catenin-deficient human mesothelioma
cellsCancer Res65743748200515705870
|
|
26.
|
AY LeeB HeL YouExpression of the secreted
frizzled-related protein gene family is downregulated in human
mesotheliomaOncogene2366726676200410.1038/sj.onc.120788115221014
|
|
27.
|
WG NelsonAM De MarzoS
YegnasubramanianEpigenetic alterations in human prostate
cancersEndocrinology15039914002200910.1210/en.2009-057319520778
|
|
28.
|
AS PerryH LiyanageM LawlerK
WoodsonDiscovery of DNA hypermethylation using a DHPLC screening
strategyEpigenetics24349200710.4161/epi.2.1.388217965617
|
|
29.
|
AS PerryB LoftusR MorooseIn silico mining
identifies IGFBP3 as a novel target of methylation in prostate
cancerBr J Cancer9615871594200710.1038/sj.bjc.660376717453001
|
|
30.
|
H EndohY YatabeS ShimizuRASSF1A gene
inactivation in non-small cell lung cancer and its clinical
implicationInt J Cancer1064551200310.1002/ijc.1118412794755
|
|
31.
|
I KuzminJW GillespieA ProtopopovThe
RASSF1A tumor suppressor gene is inactivated in prostate tumors and
suppresses growth of prostate carcinoma cellsCancer
Res6234983502200212067994
|
|
32.
|
S ToyookaHI PassN ShivapurkarAberrant
methylation and simian virus 40 tag sequences in malignant
mesotheliomaCancer Res6157275730200111479207
|
|
33.
|
K GhoshalJ DattaS
Majumder5-Aza-deoxycytidine induces selective degradation of DNA
methyltransferase 1 by a proteasomal pathway that requires the KEN
box, bromo-adjacent homology domain, and nuclear localization
signalMol Cell
Biol2547274741200510.1128/MCB.25.11.4727-4741.2005
|
|
34.
|
A SchaferL SchomacherG BarretoG DoderleinC
NiehrsGemcitabine functions epigenetically by inhibiting repair
mediated DNA demethylationPLoS
One5e14060201010.1371/journal.pone.001406021124914
|
|
35.
|
HC TsaiH LiL Van NesteTransient low doses
of DNA-demethylating agents exert durable antitumor effects on
hematological and epithelial tumor cellsCancer
Cell21430446201210.1016/j.ccr.2011.12.02922439938
|
|
36.
|
K RamachandranH MillerE GordianC
Rocha-LimaR SingalMethylation-mediated silencing of TMS1 in
pancreatic cancer and its potential contribution to
chemosensitivityAnticancer Res3039193925201021036703
|
|
37.
|
SM de LangeK van der BornJR KroepNo
evidence of gemcitabine accumulation during weekly
administrationEur J Clin Pharmacol61843849200516283278
|
|
38.
|
BR McLarenBW RobinsonRA LakeNew
chemotherapeutics in malignant mesothelioma: effects on cell growth
and IL-6 productionCancer Chemother
Pharmacol45502508200010.1007/s00280005102610854139
|
|
39.
|
VV LevensonDNA methylation as a universal
biomarkerExpert Rev Mol
Diagn10481488201010.1586/erm.10.1720465502
|
|
40.
|
F SalazarMA MolinaM
Sanchez-RoncoFirst-line therapy and methylation status of CHFR in
serum influence outcome to chemotherapy versus EGFR tyrosine kinase
inhibitors as second-line therapy in stage IV non-small-cell lung
cancer patientsLung
Cancer728491201110.1016/j.lungcan.2010.07.00820705357
|
